Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Blood (2025) 146 (Supplement 1): 802.

https://doi.org/10.1182/blood-2025-802

Published: 2025

Journal Articles

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Blood (2025) 146 (Supplement 1): 5785.

https://doi.org/10.1182/blood-2025-5785

Published: 2025

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Blood (2024) 144 (Supplement 1): 3792.4.

https://doi.org/10.1182/blood-2024-206735

Published: 2024

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

Journal Articles

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Xiang Zhou, Sarah Wiethe, Angelika Wolff, Max J Steinhardt, Nazia Afrin, Mara John, Christine Riedhammer, Xianghui Xiao, Umair Munawar, Julia Mersi, Seungbin Han, Johannes Waldschmidt, Angela Riedel, Max S. Topp, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Leo Rasche

Blood (2024) 144 (Supplement 1): 4705.

https://doi.org/10.1182/blood-2024-203391

Published: 2024

Journal Articles

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Blood (2023) 142 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2023-180032

Published: 2023

Journal Articles

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Florian Eisele, Nazia Afrin, Emilia Stanojkovska, Mara John, Moutaz Helal, Lars Grundheber, Philipp Weis, Christine Riedhammer, Sofie-Katrin Kadel, Max Steinhardt, Johannes Duell, Johannes M Waldschmidt, Hermann Einsele, Angela Riedel, K. Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2023-189042

Published: 2023

Journal Articles

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Xiang Zhou, Vivien Wagner, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Mara John, Lukas Scheller, Umair Munawar, Seungbin Han, Johannes M Waldschmidt, Max S. Topp, Johannes Duell, Hermann Einsele, Angela Riedel, Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 95.

https://doi.org/10.1182/blood-2023-180534

Published: 2023

Journal Articles

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Maximilian J Steinhardt, Max Bittrich, Xiang Zhou, Julia Noderer, Christine Riedhammer, Xianghui Xiao, Sophia Gawlas, Philipp Weis, Florian Eisele, Umair Munawar, Seungbin Han, Julia Mersi, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2023-189927

Published: 2023

Journal Articles

Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab

Anna Fleischer, Magdalena Roll, Franziska Panther, Goetz Gelbrich, Franziska Reinhardt, Christine Riedhammer, Julia Mersi, Johannes M Waldschmidt, Hermann Einsele, K. Martin Kortüm, Imad Maatouk, Leo Rasche

Blood (2023) 142 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2023-186663

Published: 2023

Journal Articles

Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Blood (2022) 140 (Supplement 1): 4273–4274.

https://doi.org/10.1182/blood-2022-163848

Published: 2022

Journal Articles

Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma

Moutaz Helal, Mara John, Emilia Stanojkovska, Greta Mattavelli, Lars Grundheber, Alexander Leipold, Nazia Afrin, Christine Riedhammer, Johannes Duell, Max Johannes Steinhardt, Julia Mersi, Hermann Einsele, Kai Kretzschmar, K. Martin Kortuem, Angela Riedel, Leo Rasche

Blood (2022) 140 (Supplement 1): 7060–7061.

https://doi.org/10.1182/blood-2022-168700

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab

Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only